March 14 (Reuters) - The U.S. Food and Drug
Administration on Thursday expanded the use of Bristol Myers
Squibb's ( BMY ) cell therapy, Breyanzi, for a type of
slow-growing blood cancer, marking the second approval for the
treatment.
(Reporting by Bhanvi Satija, Puyaan Singh and Mrinmay Dey in
Bengaluru; Editing by Shailesh Kuber and Mrigank Dhaniwala)